Tamara Isakova

Summary

Affiliation: University of Miami
Country: USA

Publications

  1. pmc Associations between fibroblast growth factor 23 and cardiac characteristics in pediatric heart failure
    Tamara Isakova
    Division of Nephrology and Hypertension, Department of Medicine, University of Miami Miller School of Medicine, 1120 NW 14th St, Miami, FL 33136, USA
    Pediatr Nephrol 28:2035-42. 2013
  2. doi request reprint Comparison of mineral metabolites as risk factors for adverse clinical outcomes in CKD
    Tamara Isakova
    Division of Nephrology and Hypertension, Department of Medicine, University of Miami, Miller School of Medicine, Miami, FL 33136, USA
    Semin Nephrol 33:106-17. 2013
  3. pmc Daily variability in mineral metabolites in CKD and effects of dietary calcium and calcitriol
    Tamara Isakova
    Division of Nephrology and Hypertension, Department of Medicine, University of Miami Miller School of Medicine, Miami, Florida 33136, USA
    Clin J Am Soc Nephrol 7:820-8. 2012
  4. pmc Pilot study of dietary phosphorus restriction and phosphorus binders to target fibroblast growth factor 23 in patients with chronic kidney disease
    Tamara Isakova
    Department of Medicine, University of Miami Miller School of Medicine, Miami, FL, USA
    Nephrol Dial Transplant 26:584-91. 2011
  5. pmc Fibroblast growth factor 23 and adverse clinical outcomes in chronic kidney disease
    Tamara Isakova
    Division of Nephrology and Hypertension, Department of Medicine, University of Miami, Miller School of Medicine, Florida 33136, USA
    Curr Opin Nephrol Hypertens 21:334-40. 2012
  6. pmc Fibroblast growth factor 23 in patients undergoing peritoneal dialysis
    Tamara Isakova
    Division of Nephrology and Hypertension, University of Miami Miller School of Medicine, Miami, FL 33136, USA
    Clin J Am Soc Nephrol 6:2688-95. 2011
  7. pmc Earlier onset and greater severity of disordered mineral metabolism in diabetic patients with chronic kidney disease
    Patricia Wahl
    Division of Nephrology and Hypertension, Department of Medicine, University ofMiami Miller School of Medicine, Miami, Florida, USA
    Diabetes Care 35:994-1001. 2012
  8. pmc Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease
    Tamara Isakova
    Division of Nephrology and Hypertension, Department of Medicine, University of Miami Miller School of Medicine, Miami, Florida, USA
    Kidney Int 79:1370-8. 2011
  9. pmc Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease
    Tamara Isakova
    Division of Nephrology and Hypertension, Department of Medicine, University of Miami, Miller School of Medicine, 1120 NW 14th St, Miami, FL 33136, USA
    JAMA 305:2432-9. 2011
  10. pmc Effects of dietary phosphate restriction and phosphate binders on FGF23 levels in CKD
    Tamara Isakova
    Division of Nephrology and Hypertension, Department of Medicine, Diabetes Research Institute, University of Miami Miller School of Medicine, Miami, Florida 33136, USA
    Clin J Am Soc Nephrol 8:1009-18. 2013

Detail Information

Publications29

  1. pmc Associations between fibroblast growth factor 23 and cardiac characteristics in pediatric heart failure
    Tamara Isakova
    Division of Nephrology and Hypertension, Department of Medicine, University of Miami Miller School of Medicine, 1120 NW 14th St, Miami, FL 33136, USA
    Pediatr Nephrol 28:2035-42. 2013
    ..In adults with heart failure, elevated levels of fibroblast growth factor 23 (FGF23) are associated with mortality. Data on FGF23 levels in pediatric heart failure are lacking...
  2. doi request reprint Comparison of mineral metabolites as risk factors for adverse clinical outcomes in CKD
    Tamara Isakova
    Division of Nephrology and Hypertension, Department of Medicine, University of Miami, Miller School of Medicine, Miami, FL 33136, USA
    Semin Nephrol 33:106-17. 2013
    ....
  3. pmc Daily variability in mineral metabolites in CKD and effects of dietary calcium and calcitriol
    Tamara Isakova
    Division of Nephrology and Hypertension, Department of Medicine, University of Miami Miller School of Medicine, Miami, Florida 33136, USA
    Clin J Am Soc Nephrol 7:820-8. 2012
    ....
  4. pmc Pilot study of dietary phosphorus restriction and phosphorus binders to target fibroblast growth factor 23 in patients with chronic kidney disease
    Tamara Isakova
    Department of Medicine, University of Miami Miller School of Medicine, Miami, FL, USA
    Nephrol Dial Transplant 26:584-91. 2011
    ..Reducing dietary phosphorus intake lowers FGF23 secretion in healthly individuals, but there is little data on its effects in patients with pre-dialysis CKD...
  5. pmc Fibroblast growth factor 23 and adverse clinical outcomes in chronic kidney disease
    Tamara Isakova
    Division of Nephrology and Hypertension, Department of Medicine, University of Miami, Miller School of Medicine, Florida 33136, USA
    Curr Opin Nephrol Hypertens 21:334-40. 2012
    ..The aim is to review data on the epidemiology of fibroblast growth factor 23 (FGF23) and adverse clinical outcomes in chronic kidney disease (CKD) and introduce recent insights into the pathophysiology behind the observed relationships...
  6. pmc Fibroblast growth factor 23 in patients undergoing peritoneal dialysis
    Tamara Isakova
    Division of Nephrology and Hypertension, University of Miami Miller School of Medicine, Miami, FL 33136, USA
    Clin J Am Soc Nephrol 6:2688-95. 2011
    ..Fibroblast growth factor 23 (FGF23) is an independent risk factor for mortality in patients with ESRD. Before FGF23 testing can be integrated into clinical practice of ESRD, further understanding of its determinants is needed...
  7. pmc Earlier onset and greater severity of disordered mineral metabolism in diabetic patients with chronic kidney disease
    Patricia Wahl
    Division of Nephrology and Hypertension, Department of Medicine, University ofMiami Miller School of Medicine, Miami, Florida, USA
    Diabetes Care 35:994-1001. 2012
    ..Although diabetes is the leading cause of CKD and is associated with worse clinical outcomes than other etiologies, few studies have evaluated mineral metabolism in CKD according to diabetes status...
  8. pmc Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease
    Tamara Isakova
    Division of Nephrology and Hypertension, Department of Medicine, University of Miami Miller School of Medicine, Miami, Florida, USA
    Kidney Int 79:1370-8. 2011
    ..Hence, FGF23 measurements may be a sensitive early biomarker of disordered phosphorus metabolism in patients with CKD and normal serum phosphate levels...
  9. pmc Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease
    Tamara Isakova
    Division of Nephrology and Hypertension, Department of Medicine, University of Miami, Miller School of Medicine, 1120 NW 14th St, Miami, FL 33136, USA
    JAMA 305:2432-9. 2011
    ....
  10. pmc Effects of dietary phosphate restriction and phosphate binders on FGF23 levels in CKD
    Tamara Isakova
    Division of Nephrology and Hypertension, Department of Medicine, Diabetes Research Institute, University of Miami Miller School of Medicine, Miami, Florida 33136, USA
    Clin J Am Soc Nephrol 8:1009-18. 2013
    ..Reducing dietary phosphate intake or absorption may decrease FGF23 levels, but data on the combined effects of dietary phosphate restriction and phosphate binders in CKD are limited...
  11. pmc Fibroblast growth factor 23 is not associated with and does not induce arterial calcification
    Julia J Scialla
    Division of Nephrology and Hypertension, Department of Medicine, University of Miami Miller School of Medicine, Miami, Florida 33136, USA
    Kidney Int 83:1159-68. 2013
    ..Thus, in contrast to serum phosphate, FGF23 is not associated with arterial calcification and does not promote calcification experimentally. Hence, phosphate and FGF23 promote cardiovascular disease through distinct mechanisms...
  12. pmc Associations of dietary phosphorus intake, urinary phosphate excretion, and fibroblast growth factor 23 with vascular stiffness in chronic kidney disease
    Jessica Houston
    Division of Nephrology and Hypertension, Department of Medicine, University of Miami Miller School of Medicine, Miami, Florida, USA
    J Ren Nutr 23:12-20. 2013
    ....
  13. pmc Racial differences in postprandial mineral ion handling in health and in chronic kidney disease
    ORLANDO M GUTIERREZ
    Division of Nephrology and Hypertension, Department of Medicine, University of Miami Miller School of Medicine, Miami, FL, USA
    Nephrol Dial Transplant 25:3970-7. 2010
    ..The aim of this study was to examine racial differences in postprandial urinary mineral ion excretion in health and in CKD...
  14. pmc Fibroblast growth factor-23 and cardiovascular events in CKD
    Julia J Scialla
    University of Miami Miller School of Medicine, Miami, Florida
    J Am Soc Nephrol 25:349-60. 2014
    ..Thus, higher FGF-23 is independently associated with greater risk of cardiovascular events, particularly CHF, in patients with CKD stages 2-4. ..
  15. doi request reprint Vitamin D deficiency, inflammation, and albuminuria in chronic kidney disease: complex interactions
    Tamara Isakova
    Division of Nephrology and Hypertension, Leonard M Miller School of Medicine, University of Miami, Miami, Florida, USA
    J Ren Nutr 21:295-302. 2011
    ..We evaluated the relationship between calcidiol (25D), calcitriol (1,25D), inflammation, and albuminuria in Study of Early Evaluation of Kidney Disease, a multicenter CKD cohort...
  16. pmc Mineral metabolites and CKD progression in African Americans
    Julia J Scialla
    Division of Nephrology and Hypertension, Department of Medicine, University of Miami Miller School of Medicine, Miami, Florida, USA
    J Am Soc Nephrol 24:125-35. 2013
    ..In conclusion, abnormalities of mineral metabolism worsen with progressive CKD and associate with higher risk for ESRD among African Americans with hypertensive nephrosclerosis...
  17. pmc Fibroblast growth factor 23, high-sensitivity cardiac troponin, and left ventricular hypertrophy in CKD
    Kelsey Smith
    Division of Nephrology and Hypertension, Department of Medicine, University of Miami Miller School of Medicine, Miami, FL 33136, USA
    Am J Kidney Dis 61:67-73. 2013
    ..We investigated the association of FGF-23 and hs-cTnI (high-sensitivity cardiac troponin I) and hs-cTnT (high-sensitivity cardiac troponin T) levels in CKD and examined the role of LVH in this association...
  18. pmc Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis
    ORLANDO M GUTIERREZ
    Renal Unit, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, USA
    N Engl J Med 359:584-92. 2008
    ..Hyperphosphatemia and low 1,25-dihydroxyvitamin D levels are associated with mortality among patients with chronic kidney disease, but the effect of the level of FGF-23 on mortality is unknown...
  19. pmc Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease
    ORLANDO M GUTIERREZ
    Division of Nephrology and Hypertension, Department of Medicine, University of Miami Miller School of Medicine, Miami, FL 33136, USA
    Circulation 119:2545-52. 2009
    ..We conducted a cross-sectional study to test the hypothesis that elevated FGF-23 concentrations are associated with left ventricular hypertrophy and coronary artery calcification in patients with CKD...
  20. doi request reprint FGF23 or PTH: which comes first in CKD ?
    Tamara Isakova
    Division of Nephrology and Hypertension, Department of Medicine, University of Miami Miller School of Medicine, Miami, Florida, USA
    Kidney Int 78:947-9. 2010
    ..However, almost 6000 papers later, fundamental pathophysiological concepts remain unclear, particularly regarding the early pathogenesis of disordered mineral metabolism...
  21. pmc (1-34) Parathyroid hormone infusion acutely lowers fibroblast growth factor 23 concentrations in adult volunteers
    ORLANDO M GUTIERREZ
    Division of Nephrology and Hypertension, Department of Medicine, University of Miami Miller School of Medicine, Miami, Florida, USA
    Clin J Am Soc Nephrol 7:139-45. 2012
    ..The extent to which this was due to a direct stimulatory effect of PTH versus an indirect effect of increasing 1,25-dihydroxyvitamin D [1,25(OH)(2)D] levels was unclear...
  22. pmc Impact of poverty on serum phosphate concentrations in the Third National Health and Nutrition Examination Survey
    ORLANDO M GUTIERREZ
    Division of Nephrology and Hypertension, Department of Medicine, University of Miami Miller School of Medicine, Miami, Florida 33136, USA
    J Ren Nutr 21:140-8. 2011
    ..We examined the impact of socioeconomic status on dietary phosphorus intake and serum phosphate concentrations in the general population...
  23. pmc Diuretics, calciuria and secondary hyperparathyroidism in the Chronic Renal Insufficiency Cohort
    Tamara Isakova
    Division of Nephrology and Hypertension, Department of Medicine, University of Miami Miller School of Medicine, Miami, FL, USA
    Nephrol Dial Transplant 26:1258-65. 2011
    ..Diuretics are widely used to control volume status and blood pressure in CKD patients but are also known to have important effects on renal calcium handling, which we hypothesized could alter the risk of secondary hyperparathyroidism...
  24. pmc Low socioeconomic status associates with higher serum phosphate irrespective of race
    ORLANDO M GUTIERREZ
    Division of Nephrology and Hypertension, Department of Medicine, University of Miami Miller School of Medicine, Miami, FL 33136, USA
    J Am Soc Nephrol 21:1953-60. 2010
    ....
  25. pmc Fibroblast growth factor 23 and Inflammation in CKD
    Jair Munoz Mendoza
    Division of Nephrology and Hypertension, Department of Medicine, University of Miami, Miller School of Medicine, Miami, FL 33136, USA
    Clin J Am Soc Nephrol 7:1155-62. 2012
    ..This study tested the hypothesis that FGF23 is independently associated with inflammation in CKD...
  26. doi request reprint A blueprint for randomized trials targeting phosphorus metabolism in chronic kidney disease
    Tamara Isakova
    Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA
    Kidney Int 76:705-16. 2009
    ....
  27. pmc FGF23 induces left ventricular hypertrophy
    Christian Faul
    Division of Nephrology and Hypertension, Department of Medicine, University of Miami Miller School of Medicine, Miami, Florida, USA
    J Clin Invest 121:4393-408. 2011
    ..These results unveil a klotho-independent, causal role for FGF23 in the pathogenesis of LVH and suggest that chronically elevated FGF23 levels contribute directly to high rates of LVH and mortality in individuals with CKD...
  28. pmc Postprandial mineral metabolism and secondary hyperparathyroidism in early CKD
    Tamara Isakova
    Renal Unit, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA
    J Am Soc Nephrol 19:615-23. 2008
    ....
  29. pmc Klotho variants and chronic hemodialysis mortality
    David J Friedman
    Center for Vascular Biology Research, Beth Israel Deaconess Medical Center, Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA
    J Bone Miner Res 24:1847-55. 2009
    ..Our data suggest that a specific Klotho variant (rs577912) is linked to survival in ESRD patients initiating chronic hemodialysis and that therapy with activated vitamin D may modify this risk...